MBRX
Moleculin Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.77
−0.88%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.44
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$1.40
- EPS estimate
- -$1.55
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +32.9%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $3.00
- PT range
- $3.00 – $3.00
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$1.55 | -$1.40 | Beat 9.68% | — |
| May 14, 2026 | -$1.69 | -$2.48 | Miss -46.75% | — |
| Mar 20, 2026 | -$7.77 | $2.61 | Beat 133.59% | — |
| Nov 13, 2025 | -$5.00 | -$3.25 | Beat 35.00% | — |
| Aug 12, 2025 | -$9.75 | -$12 | Miss -25.64% | — |
| Mar 21, 2025 | -$1.54 | -$0.37 | Beat 75.97% | — |
| May 10, 2024 | -$90 | -$51 | Beat 43.73% | — |
| Mar 22, 2024 | -$3.05 | -$5.02 | Miss -64.59% | — |
| Nov 13, 2023 | -$79 | -$71 | Beat 9.53% | — |
| Aug 11, 2023 | -$105 | -$75 | Beat 28.58% | — |
| May 11, 2023 | -$94 | -$105 | Miss -12.01% | — |
| Mar 22, 2023 | -$105 | -$90 | Beat 14.28% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026